Pharmacology of cannabinoid medication;Pharmakologische grundlagen der verwendung von cannabinoiden als medikamente

Sucht

Volumn 50, Issue 5, 2004, Pages 290-296

  Rommelspacher, Hans ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

9 tetrahydrocannabinol; Dronabinol; Medication; Nabilon; Pharmacology

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDORPHIN; MORPHINE; OPIATE; TETRAHYDROCANNABINOL;

ANALGESIA; ATAXIA; CLINICAL PHARMACOLOGY; DRUG DEPENDENCE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSTONIA; EUPHORIA; HUMAN; IN VIVO STUDY; MEMORY DISORDER; MOTIVATION; MUSCLE HYPOTONIA; PAIN; PSYCHOSIS; REVIEW; SENSORY DYSFUNCTION; SHORT TERM MEMORY; SPEECH DISORDER; THOUGHT DISORDER; TOUCH; VISUAL DISORDER; XEROSTOMIA;

EID: 8444247529     PISSN: 09395911     EISSN: None     Source Type: Journal    
DOI: 10.1463/2004.05.02     Document Type: Review

References (27)

1. Ashton, H. (2001). Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry, 178, 101-106.
2. Barnett, G., Chiang, C. W., Perez-Reyes, M. & Owens, S. M. (1982). Kinetic study of smoking marijuana. Pharmacokin. Pharmaceut. 10, 495-506.
3. Brady, C. M., Das Gupta R., Wiseman, O. J., Dalton, C. M., Berkley, K. J. & Fouler, C. J. (2002). The effects of cannabis-based medicinal extracts lower urinary tract dysfunction in advanced multiple sclerosis. Preliminary results. Journal of neurology, neurosurgery, and psychiatry, 72, 139.
4. 2 receptor. European Journal of Pharmacology, 396, 141-149.
5. Campbell, F. A., Tramer, M. R., Carroll, D., Reynolds, J. M., Moore, R. A., McQuay, H. J. (2001). Are cannabinoids an effective and safe treatment option in the management of pain? Qualitative systematic review. B.M.J. 323, 1-6.
6. Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R. & Gessa, G. L. (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sciences, 63, 113-117.
7. Duane Sofia, R. (1978). Cannabis: Structure-activity relationships. In L. L. Iversen, S. D. Iversen, S. H. Snyder (Eds.), Handbook of Psychopharmacology, vol. 12 (pp. 319-371). New York: Plenum Press.
8. ElSohly, M. A. (2001). Chemische Bestandteile von Cannabis. In F. Grotenhermen (Hrsg.), Cannabis und Cannabinoide (S. 45-55). Bern:, Verlag Hans Huber.
9. Herkenham, N., Lynn, A. B., Little, N. D., Johnson, N. R., Melvin, L. S., DeCosta, B. R. & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Science 87, 1932-1936.
10. House of Lords (1998). Cannabis. The scientific and medical evidence. London: The Stationery Office.
11. Iuvone, T., Esposito, G., Esposito, R., Satamario, R., Di Rossa & M., Izzo, A. A. (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC 12 cells. Journal of Neurochemistry, 89, 134-141.
12. 1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcoholism clinical and experimental research, 25, 1317-1323.
13. 1 receptor knockout mice. Science, 283, 401-404.
14. Lynskey, M.T., Coffey, C., Degenhardt L., Carlin, J. B. & Patton, G. (2003). A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction, 98, 685-692.
15. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
16. Meng, I.D., Manning, B. H., Martin, W. J., Fields, H. L. (1998) An analgesia circuit activated by cannabinoids. Nature, 395, 381-383.
17. Notcutt, W., Price, M., Blossfeldt, P., Chapman, G. (1999). Clinical experience of the synthetic cannabinoid nabilone for chronic pain. In G. C. Nahas, K. M. Sutin, D. J. Harvey & S. Agurell (Hrsg.), Marihuana and medicine (pp. 567-572). Totowa, N.J.: Humana Press.
18. Notcutt, W., Price, M., Sansom, C., Simmons, S., Phillips, C. (2003). Medicinal cannabis extract in chronic pain: overall results of 29 »N of 1« studies. CBME-1. In Symposion on the cannabinoids. http://www. cannabinoidsociety.org, accessed April 1,: 55.
19. Rinaldi-Carmona, M., Barth, F., Heulme, M., Shire, G., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C. & Le Fur, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters, 350, 240-244.
20. Robson, P. J., Wade, D. T., Makela, P. M. & House, H. (2003). Cannabis medicinal extracts (CME) including cannabidiol alleviated neurogenic systems in patients with multiple sclerosis and spinal cord injury. In Symposium on the cannabinoids, http://www.cannabinoidsociety.org, 56.
21. Rommelspacher, H. (1999). Cannabis. In M. Gastpar, K. Mann, H. Rommelspacher (Hrsg.), Lehrbuch der Suchterkrankungen (S. 217-220). Stuttgart: Thieme.
22. Rommelspacher, H. (2000). Cannabis: Als Arzneimittel nur von geringem therapeutischen Nutzen. Deutsches Ärzteblatt, 97, 4373-3475.
23. Salzet M., Breton C., Bisogno T. & Di Marzo, V. (2000). Comparative biology of the endocannabinoid system. European Journal of Biochemistry, 267, 4917-4927.
24. Sim, L. J., Selley, D. E., Xiao, R. & Childers, S. R. (1996). Differences in G-protein activation by μ- and δ-opioid and cannabinoid receptors in rat striatum. European Journal of Pharmcology, 307, 97-105.
25. Wiesbeck, G. A. & Schuckit, M. A., (1996). Kava, bethel nut and marijuana. In H. Rommelspacher & M. A. Schuckit (Hrsg.), Drugs of abuse (pp 563-586). London: Baillère Tindall.
26. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A. & Thompson, A. (2003). Cannabinoids for treatment of spasmicity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. The Lancet, 362, 1517-26.
27. 1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 96, 5780-5785.